Skip to main content
SpringerLink
Log in

Prostata und Samenblasen

  • Chapter
  • First Online:
Pathologie

Part of the book series: Pathologie ((PATHOL))

Zusammenfassung

Das Kapitel behandelt die ganze Pathologie der Prostata und Samenblasen, insbesondere aber die Diagnostik und Differentialdiagnostik der Tumoren. In diesem Zusammenhang werden atypische epitheliale Läsionen und Vorläuferveränderungen wie PIN, ASAP und AAH detailliert diskutiert. Weiterhin werden das neueste Malignitätsgrading und TNM-System sowie die möglichen Varianten des Prostatakarzinoms in ihrer Wertigkeit für Therapieformen und Prognoseparameter behandelt. Ebenfalls wird auf die gegenwärtige Bedeutung der molekularen Prognosemarker eingegangen. Den Abschluss bilden mesenchymale Tumoren und die Pathologie der Samenblasen. Das Kapitel ist für Pathologen und Urologen gleichermaßen informativ.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 469.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM (2003) NKX3.1; PTEN mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63:3886–3890

    CAS  PubMed  Google Scholar 

  2. Abate-Shen C, Shen MM, Gelmann E (2008) Integrating differentiation and cancer. The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 76:717–727

    PubMed Central  CAS  PubMed  Google Scholar 

  3. Abdel-Khalek M, El-Baz M, Ibrahiem H et al (2004) Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model. BJU Int 94:528–533

    PubMed  Google Scholar 

  4. Abdulkadier SA, Magee JS, Peters TJ et al (2002) Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22:1495–1503

    Google Scholar 

  5. Abrahamsson PA (1999) Neuroendocrine differentiation in prostatic carcinoma. Prostate 39:135–148

    CAS  PubMed  Google Scholar 

  6. Adlakha K, Bostwick DG (1994) Lymphoepithelioma-like carcinoma of the prostate. J Urol Pathol 2:319–325

    Google Scholar 

  7. Ahlgren G, Falkmer U, Gadaleanu V, Abrahamsson P-A (1999) Evaluation of DNA ploidy combined with a cytometric proliferation index of imprints from core needle biopsies in prostate cancer. Europ Urol 36:314–319

    CAS  Google Scholar 

  8. Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 32:81–88

    PubMed  Google Scholar 

  9. Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 32:74–80

    PubMed  Google Scholar 

  10. Amin A, Partin A, Epstein JI (2011) Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol 186:1286–1290

    PubMed  Google Scholar 

  11. Andreoiu M, Cheng L (2010) Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Human Pathol 41:781–793

    Google Scholar 

  12. Arya M, Hayne D, Brown RS, O´Donnell PJ, Mundy AR (2001) Hemangiopericytoma of the seminal cesicle presenting with hypoglycemia. J Urol 166:992

    CAS  PubMed  Google Scholar 

  13. Augustin H, Hammerer PG, Graefen M, Erbersdobler A, Blonski J, Palisaar J, Daghofer F, Huland H (2003) Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 43:455–460

    PubMed  Google Scholar 

  14. Aumüller G (1989) Morphologic and regulatory aspects of prostatic function. Anat Embryol 179:519–531

    PubMed  Google Scholar 

  15. Aumüller G, Goebel HW, Bacher M, Eicheler W, Rausch U (1993) Aktuelle morphologische und funktionelle Aspekte der Prostata. Verh Ges Pathol 77:1–18

    Google Scholar 

  16. Baschinsky DY, Niemann T, Maximo CB, Bahnson RR (1998) Seminal vesicle cystadenoma: a case report and literature review. Urology 51:840–845

    CAS  PubMed  Google Scholar 

  17. Berman DM, Yang J, Epstein JI (2000) Foamy gland high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 24:140–144

    CAS  PubMed  Google Scholar 

  18. Bañez LL, Sun L, van Leenders GJ et al (2010) Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol 184:149–156

    PubMed  Google Scholar 

  19. Berney DM, Wheeler TM, Grignon DJ et al (2011) International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol 24:39–47

    PubMed  Google Scholar 

  20. Berney DM, Algaba F, Camparo P, Compérat E, Griffiths D, Kristiansen G, Lopez-Beltran A, Montironi R, Varma M, Egevad L (2014) The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists. Histopathology 64:405–411

    PubMed  Google Scholar 

  21. Böcking A, Chatelain R, Orthen U, Gien G, von Kalckreuth G, Jocham D, Wohltmann D (1988) DNA-grading of prostatic carcinoma: Prognostic validity and reproducibility. Anticancer Res 8:129–135

    PubMed  Google Scholar 

  22. Bonkhoff H (1996) Role of the basal cells in premalignant changes of the human prostate: a stern cell concept for the development of prostate cancer. Eur Urol 30:201–205

    CAS  PubMed  Google Scholar 

  23. Bonkhoff H, Remberger K (1993) Neue Aspekte zur Histogenese von Hyperplasie und Karzinomen der Prostata. Verh Ges Pathol 77:31–39

    CAS  Google Scholar 

  24. Bonkhoff H, Remberger K (1996) Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28:98–106

    CAS  PubMed  Google Scholar 

  25. Bonkhoff H, Wheeler TM, van der Kwast TH, Magi-Galluzzi C, Montironi R, Cohen RJ (2013) Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer? Prostate 73:442–448

    CAS  PubMed  Google Scholar 

  26. Bostwick DG, Amin MB, Dunndore P, Marsh W, Schultz DS (1993) Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 24:298–301

    CAS  PubMed  Google Scholar 

  27. Bostwick DG, Cheng L (2008) Urologic surgical pathology, 2. Aufl. Mosby, St. Louis

    Google Scholar 

  28. Bostwick DG, Cheng L (2012) Precursors of prostate cancer. Histopathol 60:4–27

    Google Scholar 

  29. Bostwick DG, Montironi R (1997) Evaluating radical prostatectomy specimens: therapeutic and prognostic significance. Virchows Arch 430:1–6

    CAS  PubMed  Google Scholar 

  30. Bostwick DG, Pacelli A, Lopez-Beltran A (1996) Molecular biology of prostatic intraepithelial neoplasia. Prostate 29:117–134

    CAS  PubMed  Google Scholar 

  31. Bostwick DG, Srigley J, Grignon D, Maksem J, Humphrey P, van der Kwast TH, Bose D, Harrison J, Young RH (1993) Atypical adenomatous hyperplasia of the prostate: Morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol 24:819–832

    CAS  PubMed  Google Scholar 

  32. Brinker DA, Ross JS, Tran TA, Jones DM, Epstein JI (1999) Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade? J Urol 162:2036–2039

    CAS  PubMed  Google Scholar 

  33. Brunner A, Tzankov A, Akkad T, Lhotta K, Bartsch G, Mikuz G (2004) Wegener´s granulomatosis presenting with gross hematuria due to prostatitis. Virchows Arch 444:92–94

    CAS  PubMed  Google Scholar 

  34. Bubendorf L, Feichter GE, Obermann EC, Dalquen P (2011) Zytopathologie: Männliches Genitale: Prostata. In: Remmele Pathologie, 3. Aufl. Springer, Berlin, S 206–218

    Google Scholar 

  35. Bubendorf L, Sauter G, Moch H et al (1996) Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 148:1557–1565

    Google Scholar 

  36. Carver BS, Tran J, Gopalan A et al (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41:619–624

    PubMed Central  CAS  PubMed  Google Scholar 

  37. Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch MJ, Gasser TC (1998) Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 160:406–410

    CAS  PubMed  Google Scholar 

  38. Chan TY, Partin AW, Walsh PC, Epstein JI (2000) Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 56:823–827

    CAS  PubMed  Google Scholar 

  39. Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P (2003) A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 27:1291–1301

    PubMed  Google Scholar 

  40. Chen Z, Trotman LC, Shaffer D et al (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725–730

    PubMed Central  CAS  PubMed  Google Scholar 

  41. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM (2012) Staging of prostate cancer. Histopathol 60:87–117

    Google Scholar 

  42. Cheville JC, Reznicek MJ, Bostwick DG (1997) The focus of “atypical glands, suspicious for malignancy” in prostatic needle biopsy specimens: Incidence, histologic features, and clinical follow- up of cases diagnosed in a community practice. Am J Clin Pathol 108:633–640

    CAS  PubMed  Google Scholar 

  43. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (2007) Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 31:1246–1255

    PubMed  Google Scholar 

  44. Cuzick J, Swanson GP, Fisher G et al (2011) Transatlantic Prostate Group. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12:245–255

    PubMed Central  CAS  PubMed  Google Scholar 

  45. Dawkins HJ, Sellner LN, Turbett GR, Thompson CA, Redmond SL, McNeal JE, Cohen RJ (2000) Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasis (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression. Prostate 44:265–270

    CAS  PubMed  Google Scholar 

  46. Delahunt B, Miller RJ, Srigley JR, Evans AJ, Samaratunga H (2012) Gleason grading: past, present and future. Histopathology 60:75–86

    PubMed  Google Scholar 

  47. Deliveliotis C, Skolarikos A, Karayannis A, Tzelepis V, Trakas N, Alargof E, Protogerou V (2003) The prognostic value of p53 and DNA ploidy following radical prostatectomy. World J Urol 21:171–176

    CAS  PubMed  Google Scholar 

  48. De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992

    PubMed Central  PubMed  Google Scholar 

  49. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256–269

    PubMed Central  PubMed  Google Scholar 

  50. Denholm SW, Webb JN, Howard CCW, Cisholm GD (1992) Basaloid carcinoma of the prostate gland: Histogenesis and review of the literature. Histopathology 20:151–155

    CAS  PubMed  Google Scholar 

  51. Dhom G (1990) Unusual prostatic carcinomas. Path Res Pract 186:28–36

    CAS  PubMed  Google Scholar 

  52. Dhom G, Degro S (1982) Therapy of prostatic cancer and histopathologic follow-up. The Prostate 3:531–542

    CAS  PubMed  Google Scholar 

  53. Di Sant’Agnese PA (2001) Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 12(Suppl 2):135–140

    Google Scholar 

  54. Dong JT (2001) Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 20:173–193

    CAS  PubMed  Google Scholar 

  55. Dong F, Wang C, Farris AB, Wu S, Lee H, Olumi AF, Douglas WS, Young RH, Wu CL (2012) Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am J Surg Pathol 36:838–843

    PubMed  Google Scholar 

  56. Dundore PA, Cheville JC, Nascimento AG, Farrow GM, Bostwick DG (1995) Carcinosarcoma of the prostate. Report of 21 cases. Cancer 76:1035–1042

    CAS  PubMed  Google Scholar 

  57. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Tumours of the urinary system and male genital organs. Chapter 3: Tumours of the Prostate and seminal vesicles. WHO classification of tumours. IARC Press, Lyon

    Google Scholar 

  58. Egan AJ, Lopez-Beltran A, Bostwick DG (1997) Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. Am J Surg Pathol 21:931–935

    CAS  PubMed  Google Scholar 

  59. Egevad L (2012) Handling of radical prostatectomy specimens. Histopathol 60:118–124

    Google Scholar 

  60. Egevad L, Srigley JR, Delahunt B (2011) International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens: rationale and organization. Mod Pathol 24:1–5

    PubMed  Google Scholar 

  61. Ellwood-Yen K, Graeber TG, Wongvipat J et al (2003) MYC driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4:223–238

    CAS  PubMed  Google Scholar 

  62. Epstein JI (1994) Adenosis vs atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 18:1070–1071

    CAS  PubMed  Google Scholar 

  63. Epstein JI (2000) Gleason score 2–4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 24:477–478

    CAS  PubMed  Google Scholar 

  64. Epstein JI (2010) An update of Gleason grading system. J Urol 183:433–440

    PubMed  Google Scholar 

  65. Epstein JI (2011) Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J Urol 186:790–797

    PubMed  Google Scholar 

  66. Epstein JI (2012) Diagnosis of limited adenocarcinoma of the prostate. Histopathology 60:28–40

    PubMed  Google Scholar 

  67. Epstein JI (2013) The Gleason grading system. Wolters Kluver, Lippincott, Williams & Wilkins, Philadelphia

    Google Scholar 

  68. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) ISUP Grading Committee The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29:1228–1242

    PubMed  Google Scholar 

  69. Epstein JI, Cubilla AL, Humphrey PA (2011) Tumors of the prostate gland, seminal vesicles, penis, and scrotum (fascicle14). Washington, DC, 4th Armed Forces Institute of Pathology

    Google Scholar 

  70. Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61:1019–1024

    PubMed  Google Scholar 

  71. Epstein JI, Partin AW, Sauvageot J, Walsh PC (1996) Prediction of progression following radical prostatectomy: 
a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20:286–292

    CAS  PubMed  Google Scholar 

  72. Epstein JI, Herawi M (2006) Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 175:820–834

    PubMed  Google Scholar 

  73. Epstein JI, Hutchins GM (1984) Granulomatous prostatitis. Distinction among allergic, nonspecific and posttransurethral resection lesions. Hum Pathol 15:815–818

    Google Scholar 

  74. Erbersdobler A, Gurses N, Henke RP (1996) Numerical chromosomal changes in high-grade prostatic intraepithelial neoplasia (PIN) and concomitant invasive carcinoma. Pathol Res Pract 192:418–427

    CAS  PubMed  Google Scholar 

  75. Fain JS, Cosnow I, King BF, Zincke H, Bostwick DG (1993) Cystosarcoma phyllodes of the seminal vesicle. Cancer 71:2055–2061

    CAS  PubMed  Google Scholar 

  76. Fanning DM, Kay E, Fan Y, Fitzpatrick JM, Watson RW (2010) Prostate cancer grading: the effect of stratification of needle biopsy Gleason score 4+3 as high or intermediate grade. BJU Int 105:631–635

    PubMed  Google Scholar 

  77. Gallee MP, Ten Kate FJ, Mulder PG et al (1990) Histological grading of prostatic carcinoma in prostatectomy specimens. Comparison of prognostic accuracy of five grading systems. Br J Urol 65:368–375

    CAS  PubMed  Google Scholar 

  78. Garcia JJ, Al-Ahmadie HA, Gopalan A, Tickoo SK, Scardino PT, Reuter VE, Fine SW (2008) Do prostatic transition zone tumors have a distinct morphology. Am J Surg Pathol 32:1709–1714

    PubMed Central  PubMed  Google Scholar 

  79. Gaudin PB (1998) Histopathologic effects of radiation and hormonal therapies on benign and malignant prostate tissue. J Urol Pathol 8:55–67

    Google Scholar 

  80. Gaudin PB, Rosai J, Epstein JI (1998) Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol 22:148–162

    CAS  PubMed  Google Scholar 

  81. Gil J, Kerai P, Lleonart M et al (2005) Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res 65:2179–2185

    CAS  PubMed  Google Scholar 

  82. Glaessgen A, Hamberg H, Pihl C-G, Sundelin B, Nilsson B, Egevad L (2004) Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens. Virchows Arch 445:17–21

    PubMed  Google Scholar 

  83. Gleason DE (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50:125–128

    CAS  PubMed  Google Scholar 

  84. Gopalan A, Leversha MA, Satagopan JM et al (2009) TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69:1400–1406

    PubMed Central  CAS  PubMed  Google Scholar 

  85. Griffiths DFR, Melia J, McWilliam LJ, Ball RY, Grigor K, Harnden P, Jarmulowicz M, Montironi R, Moseley R, Waller M, Moss S, Parkinson MC (2006) A study of Gleason score interpretation in different groups of UK pathologists; techniques for improving reproducibility. Histopathology 48:655–662

    CAS  PubMed  Google Scholar 

  86. Grignon DJ, Ro JY, Ordonez NG, Ayala AG, Cleary KR (1988) Basal cell hyperplasia, adenoid basal cell tumors, and adenoid cystic carcinoma of the prostate gland. An immuno-histochemical study. Hum Pathol 19:1245–1433

    Google Scholar 

  87. Guerin D, Hasan N, Keen CE (1993) Signetring cell differentiation in adenocarcinoma of the prostate: a study of five cases. Histopathology 22:367–371

    CAS  PubMed  Google Scholar 

  88. Gurel B, Iwata T, Koh CM et al (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21:1156–1167

    PubMed Central  CAS  PubMed  Google Scholar 

  89. Häggarth L, Auer G, Busch C, Norberg M, Häggman M, Egevad L (2005) The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer. Scand J Urol Nephrol 39:387–392

    PubMed  Google Scholar 

  90. Halushka MK, Kahane H, Epstein JI (2004) Negative 34βE12 staining in a small focus of atypical glands on prostate needle biopsy: A follow-up study of 332 cases. Human Pathol 35:43–46

    CAS  Google Scholar 

  91. Hanke P, Schneider M, Götting B, Jonas D (1988) Prognose und Beurteilung von Prostatakarzinomen – ein Vergleich der Klassifikation nach Dhom und der kombinierten histologisch-zytologischen Klassifikation des onkologischen Arbeitskreises Prostatakarzinom. In: Helpap B, Senge T, Vahlensieck EW (Hrsg) Die Prostata. 4: Prostataerkrankungen. Pharm und Medical Inform, Frankfurt/Main, S 130–135

    Google Scholar 

  92. Hardeman SW, Soloway MS (1988) Transitional cell carcinoma of the prostate: diagnosis, staging and management. World J Urol 6:170–174

    Google Scholar 

  93. Hedrick L, Epstein JI (1989) Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 13:389–396

    CAS  PubMed  Google Scholar 

  94. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M et al (2012) Guidelines on prostate cancer (EAU), An update. European Association of Urology, Arnheim

    Google Scholar 

  95. Helpap B (1981) Cell kinetic and cytological grading of prostatic carcinoma. Virchows Arch A Pathol Anat Histol 393:205–214

    CAS  PubMed  Google Scholar 

  96. Helpap B (1989) Pathologie der ableitenden Harnwege und der Prostata. Springer, Berlin

    Google Scholar 

  97. Helpap B (1993) Review of the morphology of prostatic carcinoma with special emphasis on subgrading and prognosis. J Urol Pathol 1:3–20

    Google Scholar 

  98. Helpap B (1998) Differential diagnosis of glandular proliferations in the prostate. A conventional and immunohistochemical approach. Virchows Arch 433:397–405

    CAS  PubMed  Google Scholar 

  99. Helpap B (1998) Benign prostatic hyperplasia. In: Foster CS, Bostwick DG (Hrsg) Pathology of the prostate. Saunders, Philadelphia, S 66–94

    Google Scholar 

  100. Helpap B (1998) Prognosefaktoren des Prostatakarzinoms. Pathologe 19:42–52

    CAS  PubMed  Google Scholar 

  101. Helpap B (2002) Fundamentals on the pathology of prostatic carcinoma after brachytherapy. World J Urol 20:207–212

    PubMed  Google Scholar 

  102. Helpap B (2002) Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 95:1415–1420

    PubMed  Google Scholar 

  103. Helpap B (2002) Nonepithelial tumor-like lesions of the prostate: a never-ending diagnostic problem. Virchows Arch 441:231–237

    PubMed  Google Scholar 

  104. Helpap B (2006) The significance of the P504S expression pattern of the high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens. Virchows Arch 448:480–484

    CAS  PubMed  Google Scholar 

  105. Helpap B, Egevad L (2006) The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch 449:622–627

    PubMed  Google Scholar 

  106. Helpap B, Egevad L (2009) Modified Gleason Grading. An updated review. Histol Histopathol 24:661–666

    PubMed  Google Scholar 

  107. Helpap B, Egevad L (2009) Clinical insignificance of prostate cancer. Are there morphological findings? Urologe 48:170–174

    CAS  PubMed  Google Scholar 

  108. Helpap B, Klöppel G (2002) Neuroendocrine carcinomas of the prostate and urinary bladder: a diagnostic and therapeutic challenge. Virchows Arch 440:241–248

    CAS  PubMed  Google Scholar 

  109. Helpap B, Koch V (1991) Histological and immunohistochemical findings of prostatic carcinoma after external or interstitial radiotherapy. J Cancer Res Clin Oncol 117:608–614

    CAS  PubMed  Google Scholar 

  110. Helpap B, Köllermann J (1999) Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 434:385–391

    CAS  PubMed  Google Scholar 

  111. Helpap B, Köllermann (2005) Therapy induced regressive changes of prostate cancer. Pathologe 26:398–404

    CAS  PubMed  Google Scholar 

  112. Helpap B, Köllermann J (2012) Combined histoarchitectural and cytological biopsy grading improves grading accuracy in low grade prostate cancer. Int J Urol 19:126–133

    PubMed  Google Scholar 

  113. Helpap B, Oehler U (2012) Bedeutung der Zweitmeinung bei Prostatbiopsien. Pathologe 33:103–112

    CAS  PubMed  Google Scholar 

  114. Helpap B, Rübben H (1998) Prostatakarzinom. Pathologie, Praxis und Klinik. Springer, Berlin

    Google Scholar 

  115. Helpap B, Sinicina I (2002) Diagnostische Maßnahmen zur Therapieplanung des Prostatakarzinoms. Informationsaustausch zwischen Patienten – Urologen – Pathologen. Urologe 42:121–127

    Google Scholar 

  116. Helpap B, Böcking A, Dhom G, Kastendieck H, Leistenschneider W, Müller HA (1985) Klassifikation, histologisches und zytologisches Grading sowie Regressionsgrading des Prostatakarzinoms. Eine Empfehlung des pathologisch-urologischen Arbeitskreises ″Prostatakarzinom″. Pathologe 6:3–7

    CAS  PubMed  Google Scholar 

  117. Helpap B, Bostwick DG, Montironi R (1995) The significance of atypical adenomatous hyperplasia (AAH) and prostatic intraepithelial neoplasia (PIN) for the development of prostate carcinoma. An update. Virchows Arch 426:425–434

    CAS  PubMed  Google Scholar 

  118. Helpap B, Köllermann J, Oehler U (2001) Limiting the diagnosis of atypical small glandular proliferations in needle biopsies of the prostate by the use of immunohistochemistry. J Pathol 193:350–353

    CAS  PubMed  Google Scholar 

  119. Helpap B, Hartmann A, Kristiansen G, Wernert N (2013) Anleitung zur pathologisch-anatomischen Diagnostik von Prostatatumoren. Bundesverband deutscher Pathologen und Deutsche Gesellschaft für Pathologie e.V., Berlin

    Google Scholar 

  120. Helpap B, Kristiansen G, Beer M, Köllermann J, Oehler U, Pogrebniak A, Fellbaum C (2011) Improving the reproducibility of the Gleason scores in small foci of prostate cancer – Suggestion of diagnostic criteria for glandular fusion. Pathol Oncol Res 18:615–621

    PubMed  Google Scholar 

  121. Helpap B, Kristiansen G, Köllermann J, Oehler U, Fellbaum C (2012) Significance of Gleason grading of low grade carcinoma of the prostate with therapeutic option of active surveillance. Urol Int 90:17–23

    PubMed  Google Scholar 

  122. Helpap B, Ringli D, Shaikhibrahim Z, Wernert N, Kristiansen G (2013) The heterogeneous Gleason 7 carcinoma of the prostate: Analyses of low and high grade (risk) carcinomas with criteria of the International Society of Urological Pathology (ISUP). Pathol Res Pract 209:190–194

    PubMed  Google Scholar 

  123. Helpap B, Ringli D, Tonhauser J, Poser I, Breul J, Seifert H-H (2015) The significance of accurate determination of different Gleason scores for therapeutic options and prognosis of cancer prostate

    Google Scholar 

  124. Helpap B, Ringli D, Gevensleben H (2015) Proposal for a refinement of Epstein-criteria of insignificant prostate cancer

    Google Scholar 

  125. Helpap B Ringli D, Breul J, Tonhauser J, Poser I, Seifert H-H (2015) The value of rognostic grouping of prostatic carcinomas for urologists and pathologists

    Google Scholar 

  126. Herawi M, Kahane H, Cavallo C, Epstein JI (2006) Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. J Urol 175:121–124

    PubMed  Google Scholar 

  127. Hohbach CH, Dhom G (1980) Die granulomatöse Prostatitis. Eine klinische und pathoanatomische Differentialdiagnose des Prostatakarzinoms. Verh Dtsch Ges Pathol 64:244–349

    Google Scholar 

  128. Hosler GA, Epstein JI (2005) Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies. Human Pathol 36:480–485

    Google Scholar 

  129. Humphrey PA (2004) Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17:292–306

    PubMed  Google Scholar 

  130. Humphrey PA (2012) Histological variants of prostatic carcinoma and their significance. Histopathol 60:59–74

    Google Scholar 

  131. Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW, Veltri RW (2009) DNA ploidy as surrogate for biopsy Gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction. Urology 73:1092–1097

    PubMed Central  PubMed  Google Scholar 

  132. Jakse G, Kahl P, Luboldt H-J, Wernert N, Wetterauer U (2009) Pathomorphologische Untersuchungen. In: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. DGU, Düsseldorf, S 32–41

    Google Scholar 

  133. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI (2008) Validation of the contemporary Epstein criteria for insignificant prostate cancer in european men. Eur Urol 2008 54:1306–1313

    Google Scholar 

  134. Jiang Z, Wu CL, Woda BA, Dresser K, Xu J, Fanger GR, Yang YJ (2002) P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 26:1169–1174

    PubMed  Google Scholar 

  135. Kim MJ, Bhatia-Gaur R, Banach-Petrowsky WA et al (2002) Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62:2999–3004

    CAS  PubMed  Google Scholar 

  136. Klezovitch O, Risk M, Coleman I et al (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105:2105–2110

    PubMed Central  PubMed  Google Scholar 

  137. Koeneman KS, Pan CX, Jin JK, Pyle J III, Flanigan RC, Shankey TV, Diaz MO (1998) Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J Urol 160:1533–1539

    CAS  PubMed  Google Scholar 

  138. Köllermann J, Helpap B (2001) Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 116:115–121

    PubMed  Google Scholar 

  139. Köllermann J, Helpap B (2001) Neuroendocrine differentiation and short-term neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression. Eur Urol 40:313–317

    PubMed  Google Scholar 

  140. Köllermann J, Feek U, Muller H, Kaulfuss U, Oehler U, Helpap B, Köllermann MW (2000) Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol 38:714–720

    PubMed  Google Scholar 

  141. Kristiansen G (2009) Immunhistochemische Algorithmen in der Prostatadiagnostik. Pathologe 30(Suppl 2):146–153

    PubMed  Google Scholar 

  142. Kristiansen G (2012) Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 60:125–141

    PubMed  Google Scholar 

  143. Kristiansen G (2009) Konsenskonferenz der Internationalen Gesellschaft für Urologische Pathologie (ISUP) 2009 zur Diagnostik radikaler Prostatektomiepräparate. Pathologe 33:337–344

    Google Scholar 

  144. Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA et al (2007) Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 109:2432–2438

    PubMed  Google Scholar 

  145. Kunz GM Jr, Epstein JI (1998) Should each core with prostate cancer be assigned a separate Gleason score? Hum Pathol 34(911):914

    Google Scholar 

  146. Kväle R, Moller B, Wahlqvist R et al (2009) Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 103:1647–1654

    PubMed  Google Scholar 

  147. Lane Z, Epstein JI, Ajub S, Netto GJ (2008) Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features. Human Pathol 39:543–549

    Google Scholar 

  148. Lau WK, Blute M, Bostwick DG, Weaver AL, Sebo TI, Zincke H (2001) Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 166:1692–1697

    CAS  PubMed  Google Scholar 

  149. Laurila P, Leivo I, Makisalo H, Ruutu M, Miettinen M (1992) Mullerian adenosarcoma like tumor of the seminal vesicle. A case report with immunohistochemical and ultrastructural observations. Arch Pathol Lab Med 116:1072–1076

    CAS  PubMed  Google Scholar 

  150. Leite KR, Tomiyama A, Reis ST et al (2011) MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 185:1118–1122

    CAS  PubMed  Google Scholar 

  151. Levi AW, Epstein JI (2000) Pseudohyperplastic prostatic adenocarcinoma on needle biopsy and simple prostatectomy. Am J Surg Pathol 24:1039–1046

    CAS  PubMed  Google Scholar 

  152. Linke RP, Joswig R, Murphy CL (2005) Senile seminal vesicle amyloid is derived from semenogelin I. J Lab Clin Med 145:187–193

    CAS  PubMed  Google Scholar 

  153. Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wolland PC, Zincke H, Blute ML, Bostwick DG (1998) Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol 159:1497–1503

    CAS  PubMed  Google Scholar 

  154. Lorenzato M, Rey A, Durlach A, Bouttens D, Birembaut P, Staerman F (2004) DNA image cytometry on biopsies can help the detection of localized Gleason 3+3 Prostate cancers. J Urol 172:1311–1313

    CAS  PubMed  Google Scholar 

  155. Lotan TL, Epstein JI (2008) Diffuse adenosis of the peripheral zone in prostate needle biopsy and prostatectomy specimens. Am J Surg Pathol 32:1360–1366

    PubMed  Google Scholar 

  156. Lu J, Wirth GJ, Wu S, Chen J, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu CL (2012) A close surgical margin after radical prostatectomy is an independent predictor of recurrence. J Urol 188:91–97

    PubMed  Google Scholar 

  157. Magi-Galluzzi C, Evans AJ, Delahunt B et al (2011) International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. ISUP Prostate Cancer Group. Mod Pathol 24:26–38

    PubMed  Google Scholar 

  158. Maheshkumar P, Harper C, Sunderland GT, Conn IG (2000) Cystic epithelial stromal tumour of the seminal vesicle. BJU Int 85:1154

    Google Scholar 

  159. Mahlke U, Ulman A, Kunz J (1993) Prognostic significance of prostatic carcinoma grading according to Helpap. Verh Dtsch Ges Pathol 77:82–85

    CAS  PubMed  Google Scholar 

  160. Makarov DV, Sanderson H, Partin AW, Epstein JI (2002) Gleason score 7 prostate cancer on needle biopsy. Is the prognostic difference in nGleason scores 4+3 and 3+4 independent of the number of involved cores? J Urol 167:2440–2442

    PubMed  Google Scholar 

  161. Maru N, Ohori M, Kattan MW, Scardino PT, Wheeler TM (2001) Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol 32:828–833

    CAS  PubMed  Google Scholar 

  162. Mastropasqua MG, Pruneri G, Renne G, De Cobelli O, Viale G (2003) Basaloid cell carcinoma of the prostate . Case report and review of the literatur. Virchows Arch 443:787–791

    PubMed  Google Scholar 

  163. Matschke J, Erbersdobler A (2004) Extensive cerebral metastases from neuroendocrine carcinoma of the prostate. Virchows Arch 444:202–203

    PubMed  Google Scholar 

  164. McNeal JE (1989) Normal histology of the prostate. Am J Surg Pathol 12:619–633

    Google Scholar 

  165. McNeal JE, Redwine EA, Freiha FS, Stamey TA (1988) Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12:897–906

    CAS  PubMed  Google Scholar 

  166. McNeal JE, Villers A, Redwine EA, Freiha FS, Stamey TA (1990) Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66:1225–1233

    CAS  PubMed  Google Scholar 

  167. Oon SF, Watson RW, O´Leary JJ, Fitzpatrick JM (2011) Epstein criteria for insignificant prostate cancer. BJU Int 108: 518–525

    Google Scholar 

  168. Meister P, Heidl G (1991) Postoperative Spindelzellknoten der Harnblase und der Prostata. Pathologe 12:214–219

    CAS  PubMed  Google Scholar 

  169. Melia J, Moseley R, Griffiths DFR, Grigor K, Harnden P, Jarmulowicz M, McWilliliam IJ, Montironi R, Waller M, Moss SW, Parkinson MC (2006) A UK-based investigation of inter-and intra-observer reproducibility of Gleason grading of prostatic biopsies. Histopathology 48:644–654

    CAS  PubMed  Google Scholar 

  170. Minner S, Enodien M, Sirma H et al (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 17:5878–5888

    CAS  PubMed  Google Scholar 

  171. Montironi R, Muzzonigro G, Maggi Galluzzi C, Giannullis I, Diamanti L, Plito M (1994) Effect of LHRH antagonist and flutamide (combination endocrine therapy) on the frequency and location of proliferating cell nuclear antigen and apoptotic bodies in prostatic hyperplasia. J Urol Pathol 2:161–171

    Google Scholar 

  172. Montironi R, Scarpelli M, Magi Galluzzi C, Diamanti L (1992) Aneuploidy and nuclear features of prostatic intraepithelial neoplasia (PIN). J Cell Biochem 50:(Suppl 16H):47–53

    Google Scholar 

  173. Montironi R, Scattoni V, Mazzucchelli R, Lopez-Beltran A, Bostwick DG, Montorsi F (2006) Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as “atypical small acinar proliferation suspicious for but not diagnostic of malignancy”). Eur Urol 50:666–674

    CAS  PubMed  Google Scholar 

  174. Montironi R, Scarpelli M, Mazzucchelli R, Cheng L, Lopez-Beltran A (2012) The spectrum of morphology in non-neoplastic prostate including cancer mimics. Histopathology 60:41–58

    PubMed  Google Scholar 

  175. Morin G, Houlgatte A, Camparo P, Sarrazin JL, Berlizot P, Houdelette P (1998) Solitary fibrous tumor of the seminal vesicles: apropos of a case. Prog Urol 8:92–94

    CAS  PubMed  Google Scholar 

  176. Mosse CA, Magi-Galluzzi C, Tsuzuki T et al (2004) The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol 28:394–398

    PubMed  Google Scholar 

  177. Mostofi FK, Sesterhenn IA, Davis CJ (2002) Histological typing of prostate tumours. In: World Health Organization international histological classification of tumours. Springer, Berlin

    Google Scholar 

  178. Mucci NR, Rubin MA, Strawderman, MS et al (2000) Expression uf nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst 92:1941–1946

    Google Scholar 

  179. Muentener M, Hailemariam S, Dubs M, Hauri D, Sulser T (2000) Primary leiomyosarcoma of the seminal vesicle. J Urol 164:2027

    CAS  PubMed  Google Scholar 

  180. Mulholland DJ, Dedhar S, Wu H, Nelson CC (2006) PTEN and GSK3beta: Key regulators of progression to androgen-independent prostate cancer. Oncogene 35:329–337

    Google Scholar 

  181. Müller HA, Altenähr E, Böcking A, Dhom G, Faul P, Göttinger H, Helpap B, Hohbach CH, Kastendieck H, Leistenschneider G (1980) Über Klassifikation und Grading des Prostatakarzinoms. Verh Dtsch Ges Path 64:609–611

    Google Scholar 

  182. Nabi G, Ansari MS, Singh I, Sharma MC, Dogra PN (2001) Primary squamous cell carcinoma of the prostate: a rare clinicopathological entity. Report of 2 cases and review of literature. Urol Int 66:216–219

    CAS  PubMed  Google Scholar 

  183. Nazeer T, Barada IH, Fischer HAG, Ross JS (1991) Prostatic carcinosarcoma. Case report and review of literature. J Urol 146:1370–1373

    CAS  PubMed  Google Scholar 

  184. Nishimori I, Kohsaki T, Onishi S et al (2007) IgG4-related autoimmune prostatitis: two cases with or without autoimmune pancreatitis. Intern Med 46:1983–1989

    PubMed  Google Scholar 

  185. Nishiyama T, Ikarashi T, Terunuma M, Ishizaki S (2001) Osteogenic sarcoma of the prostate. Int J Urol 8:199–201

    CAS  PubMed  Google Scholar 

  186. Noguchi M, Hirabayashi Y, Kato S, Noda S (2002) Solitary fibrous tumor arising from the prostatic capsule. J Urol 168:1490–1491

    PubMed  Google Scholar 

  187. Oliai BR, Kahane H, Epstein JI (2001) A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy. Am J Surg Pathol 25:794–801

    CAS  PubMed  Google Scholar 

  188. Oliai BR, Kahane H, Epstein JI (2002) Can basal cells be seen in adenocarcinoma of the prostate? An immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol 16:1007–1012

    Google Scholar 

  189. Ormsby AH, Haskell R, Jones D, Goldblum JR (2000) Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases. Mod Pathol 13:46–51

    CAS  PubMed  Google Scholar 

  190. Osunkoya AO, Nielsen ME, Epstein JI (2008) Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy. Am J Surg Pathol 32:468–472

    PubMed  Google Scholar 

  191. Osunkoya AO, Hansel DE, Sun X, Netto G, Epstein JI (2008) Abberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol 32:461–467

    PubMed  Google Scholar 

  192. Pan CC, Chiang H, Chang YH, Epstein JI (2000) Tubulocystic clear cell adenocarcinoma arising within the prostate. Am J Surg Pathol 24:1433–1436

    CAS  PubMed  Google Scholar 

  193. Paner GPAM, Hansel DEAMB (2012) Non-epithelial neoplasms of the prostate. Histopathology 60:166–186

    PubMed  Google Scholar 

  194. Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI (2004) Prostate carcinoma with squamous differentiation. Am J Surg Pathol 28:651–657

    PubMed  Google Scholar 

  195. Perner S (2010) Dangerous Liaisons im Prostatakarzinom. Pathologe 31(Suppl 2):121–125

    PubMed  Google Scholar 

  196. Pins MR, Campbell SC, Laskin WB, Steinbronn K, Dalton DP (2001) Solitary fibrous tumor of the prostate a report of 2 cases and review of the literature. Arch Pathol Lab Med 125:274–277

    CAS  PubMed  Google Scholar 

  197. Pierorazio PM, Walsh PC, Partin AW, Epstein JI (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111:753–760

    PubMed Central  PubMed  Google Scholar 

  198. Pretorius ME, Waehre H, Abeler VM, Davidson B, Vlatkovic L, Lothe RA, Giercksky K-E, Danielsen HE (2009) Large scale genomic instability as an additive prognostic marker in early prostate cancer. Cellular Oncol 31:251–259

    CAS  Google Scholar 

  199. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB (1995) Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408–5414

    CAS  PubMed  Google Scholar 

  200. Ro JY, Grignon DJ, Ayala AG, Hogan SF, Tetu B, Ordonez NG (1988) Blue nevus and melanosis of the prostate. Electron-microscopic and immunohistochemical studies. Am J Clin Pathol 90:530–535

    CAS  PubMed  Google Scholar 

  201. Ross JS, Sheehan C, Ambros RA, Nazeer T, Jennings T, Kaufman RP, Fisher H, Rifkin MD, Kallakury BVS (1999) Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am J Surg Pathol 23:296–301

    CAS  PubMed  Google Scholar 

  202. Rubin MA, Dunn R, Kambham N, Misick CP, O’Toole KM (2000) Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy? Am J Surg Pathol 24:1634–1640

    CAS  PubMed  Google Scholar 

  203. Rubin MA, Maher CA, Chinnaiyan AM (2011) Common gene rearrangements in prostate cancer. J Clin Oncol 29:3659–3668

    CAS  PubMed  Google Scholar 

  204. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, Tiguert R, Powell IJ, Wood DP (2000) Gleason score 7 prostate cancer: A heterogeneous entity? Correlation with pathologic parameters and disease-free survival Urology 56:730–734

    CAS  PubMed  Google Scholar 

  205. Salmena L, Carracedo A, Pandolfi PP (2008) Tenets of PTEN tumor suppression. Cell 133:403–414

    CAS  PubMed  Google Scholar 

  206. Samaratunga H, Montironi R, True L et al (2011) ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol 24:6–15

    PubMed  Google Scholar 

  207. Sar M, Lubahn DB, French FS, Wilson EM (1990) Immunohistochemical localisation of the androgen receptor in rat and human tissues. Endocrinology 127:3180–3186

    CAS  PubMed  Google Scholar 

  208. Saramäki OR, Harjula AE, Martikainen PM et al (2008) TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14:3395–3400

    PubMed  Google Scholar 

  209. Saraon P, Jarvi K, Diamandis EP (2011) Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 57:1366–1375

    CAS  PubMed  Google Scholar 

  210. Sato K, Quian J, Slezak JM et al (1999) Clinical significance of alterations of chromosome 8 in high grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 91:1574–1580

    CAS  PubMed  Google Scholar 

  211. Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL, Kench JG (2012) High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int 109:1794–1800

    PubMed  Google Scholar 

  212. Sboner, Demichelis F, Calza S et al (2010) Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 3:8

    PubMed Central  PubMed  Google Scholar 

  213. Scattoni V, Roscigno M, Freshi M, Raber M, Colombo R, Bertini R, Montorsi R, Rigatti M (2005) Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies. Arch Ital Urol Androl 77:31–36

    PubMed  Google Scholar 

  214. Schaefer A, Jung M, Mollenkopf HJ et al (2010) Diagnostic and prognostic implications of microRNA profiling in prostate cancer. Int J Cancer 126:1166–1176

    CAS  PubMed  Google Scholar 

  215. Schaefer A, Jung M, Kristiansen G et al (2010) MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol 28:4–13

    CAS  PubMed  Google Scholar 

  216. Schatz P, Dietrich D, Koenig T, Burger M, Lukas A, Fuhrmann I, Kristiansen G, Stoehr R, Schuster M, Lesche R, Weiss G, Corman J, Hartmann A (2010) Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation. J Mol Diagn 12:345–353

    PubMed Central  CAS  PubMed  Google Scholar 

  217. Schlomm T, Sültmann H, Köllermann J (2009) Identizierung und Validierung klinisch relevanter molekularer Veränderungen im Prostatakarzinom. Pathologe 30:111–116

    CAS  PubMed  Google Scholar 

  218. Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, Kakudo K, Katsuoka Y (2001) Prognostic significance of neuroendocrine differentation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 51:452–459

    CAS  PubMed  Google Scholar 

  219. Sesterhenn IA, Becker RL, Avallone FA, Mostofi FK, Lin TH, Davis CL Jr. (1991) Image analysis of nucleoli and nucleolar organizer regions in prostatic hyperplasia, intraepithelial neoplasia and prostatic carcinoma. Urogenit Pathol 1:61–75

    Google Scholar 

  220. Srigley JR, Delahunt B, Evans AJ (2012) Therapy-associated effects in the prostate gland. Histopathology 60:153–165

    PubMed  Google Scholar 

  221. Srigley JR, Humphrey PA, Amin MB et al (2009) Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 133:1568–1576 (for the members of the Cancer Committee, College of the American Pathologists)

    PubMed  Google Scholar 

  222. Srigley JR, Amin MB, Bostwick DG, Grignon DJ, Hammond ME (2000) Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 124:1034–1039

    CAS  PubMed  Google Scholar 

  223. Spahn M, Kneitz S, Scholz CJ et al (2010) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127:394–403

    CAS  PubMed  Google Scholar 

  224. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA (2009) Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3? J Clin Oncol 27:3459–3464

    PubMed Central  PubMed  Google Scholar 

  225. Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366: 539–551

    Google Scholar 

  226. Sung MT, Lin H, Koch MO, Davidson DD, Cheng L (2007) Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol 31:311–318

    PubMed  Google Scholar 

  227. Tan PH, Cheng L, Srigley JR et al (2011) ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol 24:48–57

    PubMed  Google Scholar 

  228. Tavora F, Epstein JI (2008) High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate. Am J Surg 32:1060–1067

    Google Scholar 

  229. Tischler V, Fritzsche FR, Gerhardt J et al (2010) Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker. Histopathology 56:811–815

    PubMed  Google Scholar 

  230. Tomlins SA, Rhodes DR, Perner S et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648

    CAS  PubMed  Google Scholar 

  231. Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol 2013; 190: 1218–22

    Google Scholar 

  232. Tran TT, Sengupta E, Yang XJ (2001) Prostatic foamy gland carcinoma with aggressive behavior: clinicopathologic, immunohistochemical, and ultrastructural analysis. Am J Surg Pathol 25:618–623

    CAS  PubMed  Google Scholar 

  233. Uehara T, Hamano H, Kawakami M et al (2008) Autoimmune pancreatitis-associated prostatitis: distinct clinicopathological entity. Pathol Int 58:118–125

    PubMed  Google Scholar 

  234. Umehara H, Okazaki K, Masaki Y et al (2012) IgG4-related disease (IgG4RD): general concept and details. The Research Program for Intractable Disease by Ministry of Health, Labor and Welfare (MHLW) Japan G4 team. Mod Rheumatol 22:1–14

    PubMed Central  CAS  PubMed  Google Scholar 

  235. van der Kwast TH, Amin MB, Billis A et al (2011) ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 24:16–25

    PubMed  Google Scholar 

  236. Van der Kwast TH, Evans A, Lockwood G, Thachuk D, Bostwick DG, Epstein JI, Humphrey PA, Montironi R, Van Leenders GJLH, Pihl C-G, Pihl C-G, Neetens I, Kujala PM, Laurila M, Mazerolles C, Bubendorf L, Finelli A, Watson K, Srigley J (2010) Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol 34:169–177

    PubMed  Google Scholar 

  237. Varambally S, Cao Q, Mani RS et al (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322:1695–1699

    PubMed Central  CAS  PubMed  Google Scholar 

  238. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629

    CAS  PubMed  Google Scholar 

  239. Veloso SG, Lima MF, Salles PG, Berenstein CK, Scalon JD, Bambirra EA (2007) Interobserver agreement of Gleason score and modified Gleason score in needle biopsy and in surgical specimen of prostate cancer. Int Braz J Urol 33:639–646

    PubMed  Google Scholar 

  240. Veltri RW, Marlow C, Khan MA, Müller MC, Epstein JI, Partin AQW (2007) Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. Prostate 67:1202–1210

    PubMed  Google Scholar 

  241. Wang CJ (2001) Follow up of primary malignant melanoma of the prostate. J Urol 166:214

    CAS  PubMed  Google Scholar 

  242. Wang SI, Parsons R, Ittmann M (1998) Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 4:811–815

    CAS  PubMed  Google Scholar 

  243. Waring PM, Newland RC (1992) Prostatic embryonal rhabdomyosarcoma in adults. A clinicopathologic review. Cancer 69:755–762

    CAS  PubMed  Google Scholar 

  244. Weiss G, Cottrell S, Distler J et al (2009) DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 186:1678–1685

    Google Scholar 

  245. Wernert N, Goebbels R, Bonkhoff H, Dhom G (1990) Squamous cell carcinoma of the prostate. Histopathology 17:229–244

    Google Scholar 

  246. Westra WH, Grenko RT, Epstein J (2000) Solitary fibrous tumor of the lower urogenital tract: a report of five cases involving the seminal vesicles urinary bladder and prostate. Hum Pathol 31:63–68

    CAS  PubMed  Google Scholar 

  247. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, Ohori M, Scardino PT (1998) Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 29:856–862

    CAS  PubMed  Google Scholar 

  248. Wittekind C, Meyer H-J (2010) TNM-Klassifikation maligner Tumoren, 7. Aufl. Wiley-Blackwell, Hoboken. 4. korrigierter Nachdruck 2012

    Google Scholar 

  249. Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schroeder FH, van Leenders GJLH (2010) False-negative prostate needle biopsies: Frequency, histopathologic features, and follow-up. Am J Surg Pathol 34:35–43

    PubMed  Google Scholar 

  250. Yang XJ, McEntee M, Epstein JI (1998) Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67. Hum Pathol 29:1447–1450

    CAS  PubMed  Google Scholar 

  251. Yasunaga Y, Shin M, Fujita MQ, Nonomura N, Miki T, Okuyama A, Aozasa K (1998) Different patterns of p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of microdissected specimens. Lab Invest 78:1275–1279

    CAS  PubMed  Google Scholar 

  252. Yoshimura Y, Takeda S, Ieki YT et al (2006) IgG4-associated prostatitis complicating autoimmune pancreatitis. Intern Med 45:97–901

    Google Scholar 

  253. Zellweger T, Günther S, Zlobec I, Savic S et al (2009) Tumor growth fraction measured by immunohistochemical staining of K67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 124: 2116–2123

    Google Scholar 

  254. Zeng L, Rowland RG, Lele SM, Kyprianou N (2004) Apoptosis incidence and protein expression of p53, TGF-β receptor II, p27 (kip1), and smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 35:290–297

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Hegau Klinikum GmbH, Virchowstr. 10, 78207, Singen, Deutschland

    Burkhard Helpap Prof. Dr. med.

  2. Institut für Pathologie, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland

    Glen Kristiansen Prof. Dr.

Authors
  1. Burkhard Helpap Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glen Kristiansen Prof. Dr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Burkhard Helpap Prof. Dr. med. .

Editor information

Editors and Affiliations

  1. Abt. Nephropathologie, Pathologisches Institut Universität Erlangen-Nürnberg, Erlangen, Germany

    Kerstin Amann

  2. Klinisches Institut für Pathologie, Medizinische Universität Wien Allg. Krankenhaus der Stadt Wien, Wien, Austria

    Renate Kain

  3. Konsultationszentrum für Pankreas- und Endokrine Tumoren, Institut für Pathologie, Ismaninger Str. 22, 81675, Technische Universität München Klinikum rechts der Isar, München, Germany

    Günter Klöppel

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Helpap, B., Kristiansen, G. (2016). Prostata und Samenblasen. In: Amann, K., Kain, R., Klöppel, G. (eds) Pathologie. Pathologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-04566-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-04566-0_4

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-04565-3

  • Online ISBN: 978-3-642-04566-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation